Healthcare company Perrigo Company plc (NYSE:PRGO) (TASE:PRGO) reported on Wednesday the receipt of final approval from the US Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing Mycolog II Cream (nystatin and triamcinolone acetonide cream USP, 100,000 units/gram and 1 mg/gram).
In the Q4 2017, the company is expected to introduce its AB Rated generic version of Mycolog II Cream in the commercial market in the US.
The company said the Mycolog II Cream is indicated for the treatment of cutaneous candidiasis.
For the 12 months ended June 2017, the annual market sales for Mycolog II Cream was approximately USD93m, according to the company.
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS